Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336465 | 1.00 | CYP11B1 (0.51) | CYP11B1CYP11B2NOTUMHTTALDH1A1 | |
| SCHEMBL30002805 | 0.87 | LMNA (0.47) | CYP11B1CYP11B2NOTUMHTTALDH1A1 | |
| SCHEMBL1633910 | 0.87 | LMNA (0.47) | CYP11B1CYP11B2NOTUMHTTALDH1A1 | |
| SCHEMBL154510 | 0.80 | CYP11B1 (0.52) | CYP11B1CYP11B2NOTUMHTTALDH1A1 | |
| SCHEMBL2334976 | 0.80 | CYP11B1 (0.52) | CYP11B1CYP11B2NOTUMHTTALDH1A1 | |
| SCHEMBL21605968 | 0.79 | ALDH1A1 (0.44) | CYP11B1CYP11B2NOTUMHTTALDH1A1 | |
| SCHEMBL1669818 | 0.79 | PDE10A (0.50) | CYP11B1CYP11B2NOTUMHTTALDH1A1 | |
| SCHEMBL25443617 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2NOTUMHTTALDH1A1 | |
| SCHEMBL6793277 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2NOTUMHTTALDH1A1 | |
| SCHEMBL21893788 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2NOTUMHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-30 | — | — | US | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230399332-A1 | IMIDAZO[1,2-a]PYRAZINE OR PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND USE THEREOF | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399332-A1 | IMIDAZO[1,2-a]PYRAZINE OR PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND USE THEREOF | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2023179078-A1 | IMIDAZO [1,2-A] PYRAZINE OR PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVE AND USE THEREOF | 腾讯科技（深圳）有限公司 | 2023-09-28 | — | — | WO | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-1458392-B1 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION | 2009-02-12 | — | — | US | disclosed |
| US-7468446-B2 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION (US) | 2008-12-23 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1794139-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006028963-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052596-A1 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION | 2006-03-09 | — | — | US | disclosed |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | IMPDH2, IMPDH1, XDH | CYP11B1 591/4885CYP11B2 460/4885NOTUM 1752/4885 |
| US-20230399332-A1 | IMIDAZO[1,2-a]PYRAZINE OR PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND USE THEREOF | CYP2D6, UGT1A1, TPMT | CYP11B1 18/4885CYP11B2 14/4885NOTUM 3931/4885 |
| US-20060052596-A1 | Substituted heterocyclic compounds and uses thereof | NQO1, LTC4S, VHL | CYP11B1 6/4885CYP11B2 5/4885NOTUM 611/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | CYP11B1 2100/4885CYP11B2 2623/4885NOTUM 1944/4885 |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | CYP11B1 229/4885CYP11B2 210/4885NOTUM 4702/4885 |
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | NQO1, LTC4S, VHL | CYP11B1 6/4885CYP11B2 5/4885NOTUM 611/4885 |
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | CYP11B1 374/4885CYP11B2 359/4885NOTUM 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.